Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | > 5 mg ear-1 | In vivo inhibition of AA induced ear oedema in mice following topical administration. | ChEMBL. | 2213827 |
ED50 (functional) | > 5 mg ear-1 | In vivo inhibition of AA induced ear oedema in mice following topical administration. | ChEMBL. | 2213827 |
IC50 (binding) | > 50 uM | In vitro for prostaglandin G/H synthase inhibitory activity against rat basophil leukemia type 1 cell homogenates, by measuring the radioactivity of [14C]-PGD2 | ChEMBL. | 2213827 |
IC50 (binding) | = 50 uM | Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation) | ChEMBL. | 2213827 |
IC50 (binding) | = 50 uM | In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay) | ChEMBL. | 2213827 |
IC50 (binding) | > 50 uM | In vitro for prostaglandin G/H synthase inhibitory activity against rat basophil leukemia type 1 cell homogenates, by measuring the radioactivity of [14C]-PGD2 | ChEMBL. | 2213827 |
IC50 (binding) | = 50 uM | Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation) | ChEMBL. | 2213827 |
IC50 (binding) | = 50 uM | In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay) | ChEMBL. | 2213827 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.